Article Text

Download PDFPDF
I13 Striatal regulation of cholesterol metabolism by CYP46A1 is associated with multiple benefits in huntington’s disease knock-in mice models
  1. Radhia Kacher1,
  2. Vincent Kappes1,
  3. Antonin Lamazière2,
  4. Nicolas Heck1,
  5. Gaëtan Despres2,
  6. Luliia Dembitskaia3,
  7. Elodie Perrin3,
  8. Wilhem Christaller4,
  9. Satish Sasidharan Nair5,
  10. Valérie Messent6,
  11. Laurent Venance3,
  12. Frédéric Saudou4,
  13. Christian Néri5,
  14. Peter Vanhoutte1,
  15. Jocelyne Caboche1,
  16. Sandrine Betuing1
  1. 1Neuronal Signaling and Gene Regulation, Neurosciences Paris Seine, Institut de Biologie Paris-Seine, Sorbonne Universités, Université Pierre et Marie Curie-Paris 6, INSERM/UMR-S 1130, CNRS/UMR 8246, Paris, France
  2. 2LBM, Sorbonne Universités- Université Pierre et Marie Curie-Paris 6, CHU Saint-Antoine, Paris, France
  3. 3Dynamic and Pathophysiology of Neuronal Networks, Center for Interdisciplinary Research in Biology, Centre National de la Recherche Scientifique, Unité Mixte de Recherche 7241/INSERM U1050, Collège de France, Paris, France
  4. 4Grenoble Institut des Neurosciences, Université Grenoble Alpes, INSERM U1216, CHU Grenoble Alpes,Grenoble, France
  5. 5Sorbonnes Université, Centre National de la Recherche Scientifique, Research Unit Biology of Adaptation and Aging (B2A), Team Compensation in Neurodegenerative and Aging (Brain-C), Paris, France
  6. 6Neuroplasticity of Reproductive Behaviors, Sorbonne Université, CNRS, INSERM, Neurosciences Paris Seine, Institut de Biologie Paris Seine, Paris, France

Abstract

Background Recently, altered brain cholesterol homeostasis has been implicated in Huntington’s disease (HD) pathogenesis. Our team made the original observation that expression level of CYP46A1, the rate-limiting enzyme for the degradation of cholesterol in the brain, is decreased in putamen extracts of post-mortem HD patients and in the striatum of an HD knock-in (KI) mouse model, the zQ175 mice.

Method We restored CYP46A1 expression into the striatum of zQ175 mice, at a pre-symptomatic stage, using an AAV-mediated approach. A battery of behavioral, neuropathological and molecular tests was performed in these mice.

Results In zQ175 mice injected with CYP46A1, locomotor activity and histological landmarks were improved; aggregates number and size were decreased and striatal projection neurons soma size was increased. In these mice, cholesterol homeostasis is restored with not only an increase of cholesterol degradation but also a regulation of cholesterol synthesis, with increased cholesterol precursor’s levels, thus a regulation of the whole pathway. Complementary studies showed that CYP46A1 improves the synaptic connectivity and the glutamatergic transmission in the striatum of zQ175 mice. Additionally, we showed that CYP46A1 increases BDNF vesicle axonal transport as well as TrkB receptor endosome trafficking in HD cortico-striatal connections reconstituted in microfluidic devices. Finally, we report that CYP46A1-regulated sterols, lanosterol and desmosterol, increased the clearance of mHTT aggregates through proteasome and autophagy machineries.

Conclusion In the present project, we showed that CYP46A1 restoration alleviates the pathological phenotype of zQ175 mice. Collectively, our results provide a comprehensive model for the mechanisms by which CYP46A1 striatal restoration may promote brain homeostasis and oppose HD, opening a novel therapeutic avenue based on promoting compensation of HD phenotype.

  • Neuroprotection
  • cholesterol
  • CYP46A1
  • zQ175

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.